Core Insights - Bausch Health reported $2.26 billion in revenue for Q1 2025, a year-over-year increase of 4.9%, with EPS remaining unchanged at $0.59 compared to the previous year [1] - The revenue fell short of the Zacks Consensus Estimate of $2.27 billion, resulting in a surprise of -0.54%, while the EPS missed the consensus estimate of $0.83 by -28.92% [1] Revenue Breakdown - Bausch + Lomb - Ophthalmic Pharmaceuticals: $267 million, below the estimate of $285.29 million, with no year-over-year change [4] - Solta Medical: $113 million, exceeding the estimate of $105.12 million, representing a year-over-year increase of 28.4% [4] - Bausch + Lomb - Vision Care: $656 million, slightly below the estimate of $657.80 million, with a year-over-year increase of 3.3% [4] - Total Bausch Health (excluding B+L): $1.12 billion, matching the estimate, with a year-over-year increase of 6.5% [4] - Total Bausch + Lomb revenues: $1.14 billion, below the estimate of $1.16 billion, with a year-over-year increase of 3.5% [4] - Diversified Products: $205 million, exceeding the estimate of $201.28 million, with a year-over-year increase of 1.5% [4] - Bausch + Lomb - Surgical: $214 million, slightly above the estimate of $212.34 million, with a year-over-year increase of 8.6% [4] - Salix: $542 million, below the estimate of $544.67 million, with a year-over-year increase of 8.6% [4] - International revenues: $262 million, below the estimate of $267.63 million, with a year-over-year decrease of 1.1% [4] - Product sales: $2.23 billion, slightly below the estimate of $2.24 billion, with a year-over-year increase of 4.6% [4] - Other revenues: $32 million, exceeding the estimate of $22.60 million, with a year-over-year increase of 33.3% [4] - Diversified Products - Dentistry: $23 million, below the estimate of $23.77 million, with a year-over-year decrease of 4.2% [4] Stock Performance - Bausch shares have returned -11.8% over the past month, compared to the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Bausch Health (BHC) reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share, indicating an earnings surprise of -28.92% [1] Financial Performance - The company posted revenues of $2.26 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.54%, compared to revenues of $2.15 billion a year ago [2] - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Bausch shares have declined approximately 31.6% since the beginning of the year, contrasting with the S&P 500's decline of -5.5% [3] - The current Zacks Rank for Bausch is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05 on revenues of $2.46 billion, and for the current fiscal year, it is $4.26 on revenues of $9.92 billion [7] - The estimate revisions trend for Bausch is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 98-0448205 (State or o ...

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano (877) 281-6642 (toll free) (908) 541-3785 ir@bauschhealth.com corporate.communications@bauschhealth.com BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2025 RESULTS LAVAL, QC, April 30, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2025 financial results and other key updates from th ...

Company Overview - Bausch Health (BHC) is expected to report a year-over-year increase in earnings, with a projected EPS of $1.44, reflecting a change of +144.1% [3] - Revenues are anticipated to reach $2.27 billion, marking a 5.5% increase from the previous year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 3.44% over the last 30 days, indicating a bearish sentiment among analysts [4] - The Most Accurate Estimate for Bausch is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -35.93%, which complicates the prediction of an earnings beat [10][11] Historical Performance - In the last reported quarter, Bausch exceeded the consensus EPS estimate of $1.12 by delivering earnings of $1.15, resulting in a surprise of +2.68% [12] - Over the past four quarters, Bausch has beaten consensus EPS estimates two times [13] Market Sentiment - The stock's movement is contingent on the upcoming earnings report, with potential for an increase if results exceed expectations, while a miss could lead to a decline [2] - Despite the negative Earnings ESP, the stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [11] Industry Context - BridgeBio Pharma (BBIO), a peer in the Zacks Medical - Generic Drugs industry, is expected to report a significant decline in earnings, with an EPS estimate of $0.91, reflecting a year-over-year change of -1,720% [17] - BridgeBio's revenues are projected to be $62.45 million, down 70.4% from the previous year [17] - The consensus EPS estimate for BridgeBio has been revised down by 1.8% over the last 30 days, but a higher Most Accurate Estimate has resulted in a positive Earnings ESP of 0.24% [18]

Company Overview - Bausch Health (BHC) shares increased by 13.3% to close at $5.10, following a district court ruling in favor of the company and its gastroenterology business Salix Pharmaceuticals against Norwich regarding the generic version of Xifaxan [1] - The stock had previously experienced a 35.7% loss over the past four weeks, indicating a significant recovery [1] Earnings Expectations - Bausch is expected to report quarterly earnings of $1.46 per share, reflecting a year-over-year increase of 147.5% [2] - Revenue projections stand at $2.27 billion, which is a 5.5% increase compared to the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Bausch has remained unchanged over the last 30 days, suggesting stability in earnings expectations [3] - The stock's price movement is typically correlated with trends in earnings estimate revisions, indicating that future performance should be monitored closely [3] Industry Context - Bausch operates within the Zacks Medical - Generic Drugs industry, where Doctor Reddy's (RDY) also competes, having a Zacks Rank of 3 (Hold) and a recent stock price increase of 1.7% to $13.67 [3][4] - Doctor Reddy's has an unchanged consensus EPS estimate of $0.20 for the upcoming report, representing a 5.3% increase from the previous year [4]

Group 1 - One-eighth of the world's population, approximately 970 million people, suffers from some form of mental health condition [1] - In the United States, nearly 70 million people, which is one-fifth of adults, are affected by mental health issues [1] Group 2 - Ari Zoldan is the CEO of Quantum Media Group, a marketing and media agency based in New York City [1] - Zoldan is an on-air TV personality featured on networks such as FOX, CNN, and CNBC, focusing on technology, media, and business trends [1] - He serves as Chair of the Media & Development committee for The Zahn Center for Innovation at City College [1] - Zoldan has reported from various war-torn and conflicted regions, including South Sudan, Uganda, Nicaragua, Haiti, Burma, and Guinea [1] - He holds press credentials for Capitol Hill and the United Nations and is a member of the National Press Club in Washington, DC [1]

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1][2] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]

Group 1 - The article highlights Chris Lau as an experienced investor and economist with a focus on life science, technology, and dividend-growth income stocks [1] - The investing group DIY Value Investing shares top stock picks of undervalued stocks with catalysts for upside and dividend-income recommendations [1] - The average returns from public articles show a significant increase over the years, with 2023 at 8.4%, 2022 at 6.9%, 2021 at 29.9%, and 2020 at 49.9% [2] Group 2 - The flagship products include top DIY picks that are undervalued stocks with upcoming catalysts that the market does not expect [2] - Dividend-income champions are highlighted for their long history of dividend growth, accompanied by a printable calendar and quantitative scores [3] - DIY risky picks are mentioned for speculative allocations with positive momentum, aiming for potential triple returns [3]

Core Insights - Bausch Health Companies Inc. (BHC) reported better-than-expected fourth-quarter results, with shares gaining 2.36% and 7.8% in aftermarket trading [1][2] - Adjusted earnings per share (EPS) of $1.15 exceeded the Zacks Consensus Estimate of $1.12, remaining flat year over year [1][2] - Total revenues reached $2.56 billion, a 6% increase year over year, surpassing the Zacks Consensus Estimate by 1.89% [2] Revenue Breakdown - Salix segment revenues were $634 million, up 9% year over year, driven by strong demand for Xifaxan, which saw a 16% increase [3][4] - International revenues totaled $279 million, down 4% year over year, missing estimates due to declines in Latin America [5] - Solta Medical reported revenues of $138 million, a 34% increase year over year, significantly beating estimates [6] - Bausch + Lomb revenues amounted to $1.3 billion, up 9% year over year, also exceeding estimates [8] Annual Performance - For the full year, BHC reported revenues of $9.62 billion, a 10% increase year over year, surpassing the Zacks Consensus Estimate [9] - Adjusted EPS for the year was $3.75, beating the Zacks Consensus Estimate of $3.73 [9] Pipeline Development - The phase II study on amiselimod for ulcerative colitis has completed enrollment, with a phase III study protocol submitted to the FDA [10] - Phase III studies for rifaximin in hepatic encephalopathy are ongoing, with top-line results expected by early 2026 [11] - The Clear and Brilliant Touch program for skin rejuvenation is advancing, with multiple international approvals received [12] Future Guidance - BHC expects 2025 revenues to range from $9.9 billion to $10.15 billion, with Bausch + Lomb revenues anticipated between $4.95 billion and $5.05 billion [13] Financial Strategy - BHC's subsidiary entered a financing commitment for a senior secured credit facility of up to $700 million, aimed at repaying 2025 and 2026 debt obligations [15][16]